Lilly links COVID-19 antibody to a reduce hospitalization rate
Eli Lilly has linked its anti-SARS-CoV-2 antibody to a lower rate of hospitalization in patients lately diagnosed with mild to moderate cases of COVID-19. Nevertheless, two of the three doses, including the highest studied in the phase 2 trial, flunked to beat placebo in terms of decreasing viral load by Day 11.
The study, BLAZE-1, evaluated the effect of three doses of LY-CoV555 and placebo in 452 patients with mild to moderate COVID-19 symptoms and a positive SARS-CoV-2 test based on a sample taken no more than three days before dosing.
The primary endpoint of Lilly looked at the cha...